Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
This study has been completed.
Study NCT00067080   Information provided by Novartis
First Received: August 11, 2003   Last Updated: September 21, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anemia, Sickle Cell
Additional conditions recognized in this trial
Hemosiderosis
Iron Overload
More general conditions related to this trial
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Iron Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
ICL670
deferoxamine
Additional drug interventions recognized in this trial
Deferasirox
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Siderophores
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services